Abiopharma

🔍 Chang Mike F (Director)

Company: ALPHA & OMEGA SEMICONDUCTOR Ltd (AOSL)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Sold 3,000,000 shares of Common Shares (Direct)
  Date: 2026-08-13 | Code: G | equity_swap_involved: 0 | shares_owned_after: 560,540.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Shares (Direct)
  Date: 2026-08-13 | Code: H | nature_of_ownership: By CHANG TRUST | shares_owned_after: 3,799,786.00

Footnotes:

• F1: On August 13, 2026, the reporting person transferred 3,000,000 common shares to the CHANG TRUST for no consideration. The reporting person is the trustee of the trust, and members of the reporting person's immediately family are the sole beneficiaries of the trust. The reporting person remains the beneficial owner of the securities held by the trust.
• F2: Includes 35,625 unvested shares subject to the Performance Share Unit (PSU) granted on March 15, 2024 and March 17, 2025 which are subject to vesting upon satisfaction of service-based vesting conditions by the Reporting Person.
• F3: Includes 45,000 unvested shares subject to the Market-Based Performance Share Unit (MSU) granted on July 1, 2018 which are subject to vesting upon satisfaction of service-based vesting conditions by the Reporting Person.
• F4: Includes an aggregate of 67,500 shares subject to Restricted Share Unit awards (RSU) granted on March 15, 2023, March 15, 2024, March 17, 2025, and March 16, 2026 which will be issued as such units vest in accordance with their terms, and excludes 22,500 unvested common shares subject to the PSU granted on March 16, 2026, which may become vested upon achievement of certain corporate performance goals in the future.